NervGen PharmaNGEN -1.06%22 PB Ratio is 58.44 as of Jun. 27, 2026. GuruFocus rates NGEN with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, NervGen Pharma ranks worse than 99.03% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), NervGen Pharma's share price is $1.87. NervGen Pharma's Book Value per Share for the quarter that ended in Mar. 2026 was $0.03. Hence, NervGen Pharma's PB Ratio of today is 58.44.
The historical rank and industry rank for NervGen Pharma's PB Ratio or its related term are showing as below:
NGEN'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 117.05
Current: 117.05
During the past 9 years, NervGen Pharma's highest PB Ratio was 117.05. The lowest was 0.00. And the median was 0.00.
NGEN's PB Ratio is ranked worse than 99.03% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs NGEN: 117.05
During the past 12 months, NervGen Pharma's average Book Value Per Share Growth Rate was 18.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -42.30% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of NervGen Pharma was 58.20% per year. The lowest was -53.30% per year. And the median was -18.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
NervGen Pharma PB Ratio Related Terms
NervGen Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for NervGen Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NervGen Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NervGen Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NervGen Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where NervGen Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
NervGen Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
NervGen Pharma (NGEN) has a PB Ratio of 58.44 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NervGen Pharma and its competitors. According to the industry distribution chart, NervGen Pharma ranks #1220 out of 1232 companies in the Biotechnology industry, placing it in the top 99%.
Is NervGen Pharma's PB Ratio too high?
NervGen Pharma's current PB Ratio is 58.44. The Biotechnology industry median PB Ratio is 2.80. NervGen Pharma's value of 58.44 is 1987.1% above this industry median. Based on the distribution chart, NervGen Pharma ranks #1220 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NervGen Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's PB Ratio compare to CNTN and ELTX?
According to the Biotechnology industry distribution chart, NervGen Pharma ranks #1220 out of 1232 companies for PB Ratio. This places NervGen Pharma in the lower half of its industry. The industry median PB Ratio is 2.80. NervGen Pharma's value of 58.44 is 1987.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NervGen Pharma's current PB Ratio of 58.44 is 1987.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NervGen Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NervGen Pharma's current PB Ratio is 58.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (NGEN) has a current PB Ratio of 58.44. The current PB Ratio is 58.44 and 1987.1% above the Biotechnology industry median of 2.80. NervGen Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For NervGen Pharma (NGEN), the current PB Ratio is 58.44 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score
Get the complete analysis for NGEN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGEN has been successfully added to your 
